Speaking of “special products” from agricultural biodiversity, check this out.
African medicinal plants
Two stories appeared today on medicinal plants in South Africa. AllAfrica has an article on the launch of the Medicinal Plant Incubator Project (MPIP) at the Agricultural Research Council (ARC) in Roodeplaat, although actually I found the keynote address delivered at the opening ceremony much more interesting. What will MPIP do? According to another article:
Gauteng’s traditional healers are to be taught new methods to cultivate plants and harvest them from the wild, in an attempt to ensure that the local medicine chest remains full for future generations.
Meanwhile, EurekAlert describes how “a team of researchers has now examined the effectiveness of 16 plants growing in the country’s Kwa-Zulu Natal region and concluded that eight plant extracts may hold value for treating high blood pressure (hypertension).”
Chinese fungi and tea
I’m killing a few hours at Hong Kong International Airport, so I pick up the latest issue of China Today. There’s a number of really interesting articles, but two little snippets jumped out at me. The first is a short note on the Chinese Caterpillar Fungus, Cordyceps sinensis. No, I’d never heard of it either, but it turns out that it is important in Chinese traditional medicine, and that it has not been possible to grow it in the lab. Until just now that is, hence the note in the Sci-tech Info section announcing the possibility of mass-production.
The other really nifty piece of sino-information occurs in the opening section of an Around China piece on the Zhenyuan Yi-Hani-Lanu Autonomous County. It seems that this ancient tea-growing area, with its tea-dominated forests, boasts what is considered the oldest and largest tea plant in the world. At 25 metres tall, almost 3 metres in diameter and an alleged 2,700 years of age, it is apparently quite the tourist attraction, and “its fleshy, glossy leaves produce a strong and lasting flavour.”
More on gorilla medicine
It’s wonderful what happens when a real expert gets stuck into a question. Back in November, Luigi briefly blogged a story about pharmaceutical researchers who derived some inspiration from gorillas and their liking for a particular plant. In the comments, Kathryn Garforth Mitchell wondered about the access and benefit sharing aspects of the story. Luigi, characteristically, had no idea, feared for the worst, and hoped he was wrong. Well, maybe his hopes were not in vain, because Kathryn has spent the past four months ferreting out the details and piecing most of the story together. The result is an illuminating series of posts that shows just how complex arrangements can be. I’m not going to link to all four of them; you should start at number one — Gorilla medicine: a complex web — and work your way through them.
One interesting point of direct relevance. Scientists in the US say that they may source the active compounds from plants grown locally in Nigeria or Ghana. This is very atypical of pharmaceutical arrangements, which usually involve discovering the active ingredient in a plant and then synthesizing it chemically. It is also, perhaps, the biggest source of confusion for those interested in access and benefit sharing of specifically agricultural products. While genes may be discovered in farmer varieties and wild relatives, the value of those genes never derives from the manufacture of the gene’s products.